SELLAS Life Sciences Group Sees Unusually High Options Volume (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the target of unusually large options trading on Tuesday. Stock investors acquired 75,479 call options on the company. This represents an increase of approximately 114% compared to the typical daily volume of 35,245 call options.

SELLAS Life Sciences Group Stock Performance

Shares of SLS traded down $1.00 during mid-day trading on Tuesday, reaching $9.84. 6,109,073 shares of the company were exchanged, compared to its average volume of 8,483,030. SELLAS Life Sciences Group has a 52 week low of $1.39 and a 52 week high of $15.88. The stock has a market capitalization of $1.93 billion, a PE ratio of -42.57 and a beta of 2.42. The business has a 50 day simple moving average of $10.43 and a two-hundred day simple moving average of $6.70.

SELLAS Life Sciences Group (NASDAQ:SLS) last announced its earnings results on Tuesday, May 12th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.01.

Analyst Upgrades and Downgrades

SLS has been the subject of several research reports. Alliance Global Partners reiterated a “buy” rating on shares of SELLAS Life Sciences Group in a research report on Monday, July 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research note on Friday, July 17th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $10.00.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Several large investors have recently modified their holdings of SLS. Larson Financial Group LLC bought a new position in SELLAS Life Sciences Group during the fourth quarter worth $26,000. BNP Paribas Financial Markets lifted its holdings in SELLAS Life Sciences Group by 89.2% in the third quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock valued at $32,000 after buying an additional 9,299 shares during the period. Concurrent Investment Advisors LLC bought a new stake in SELLAS Life Sciences Group during the fourth quarter valued at $38,000. Beacon Pointe Advisors LLC bought a new stake in SELLAS Life Sciences Group during the fourth quarter valued at $38,000. Finally, California State Teachers Retirement System grew its holdings in SELLAS Life Sciences Group by 22.4% during the 1st quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock worth $39,000 after acquiring an additional 1,709 shares during the period. 17.38% of the stock is currently owned by institutional investors and hedge funds.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.